Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Shares Outstanding (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Shares Outstanding for 7 consecutive years, with $27.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.27% to $27.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.0 million through Dec 2025, up 1.27% year-over-year, with the annual reading at $27.0 million for FY2025, 1.27% up from the prior year.
  • Shares Outstanding hit $27.0 million in Q4 2025 for Eton Pharmaceuticals, up from $26.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $25.7 billion in Q1 2024 to a low of $24.5 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $1.3 billion across 5 years, with a median of $25.6 million in 2023.
  • Biggest five-year swings in Shares Outstanding: soared 100630.01% in 2024 and later plummeted 99.9% in 2025.
  • Year by year, Shares Outstanding stood at $24.6 million in 2021, then rose by 2.95% to $25.4 million in 2022, then grew by 1.32% to $25.7 million in 2023, then grew by 3.97% to $26.7 million in 2024, then increased by 1.27% to $27.0 million in 2025.
  • Business Quant data shows Shares Outstanding for ETON at $27.0 million in Q4 2025, $26.8 million in Q3 2025, and $26.8 million in Q2 2025.